Activity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer

Radosław Polański1, Cassandra L. Hodgkinson1, Alberto Fusi4, Daisuke Nonaka4, Lynsey Priest1,4, Paul Kelly1, Francesca Trapani1, Paul W. Bishop5, Anne White2,3, Susan E. Critchlow6, Paul D. Smith6, Fiona Blackhall1,4, Caroline Dive1, and Christopher J. Morrow1

Abstract

Purpose: The monocarboxylate transporter 1 (MCT1) inhibitor, AZD3965, is undergoing phase 1 evaluation in the United Kingdom. AZD3965 is proposed, via lactate transport modulation, to kill tumor cells reliant on glycolysis. We investigated the therapeutic potential of AZD3965 in small cell lung cancer (SCLC) seeking rationale for clinical testing in this disease and putative predictive biomarkers for trial use.

Experimental Design: AZD3965 sensitivity was determined for seven SCLC cell lines, in normoxia and hypoxia, and for a tumor xenograft model. Proof of mechanism was sought via changes in intracellular/tumor lactate. Expression of MCT1 and related transporter MCT4 was assessed by Western blot analysis. Drug resistance was investigated via MCT4 siRNAi and overexpression. The expression and clinical significance of MCT1 and MCT4 were explored in a tissue microarray (TMA) from 78 patients with SCLC.

Results: AZD3965 sensitivity varied in vitro and was highest in hypoxia. Resistance in hypoxia was associated with increased MCT4 expression. In vivo, AZD3965 reduced tumor growth and increased intratumor lactate. In the TMA, high MCT1 expression was associated with worse prognosis (P = 0.014). MCT1 and hypoxia marker CA IX expression in the absence of MCT4 was observed in 21% of SCLC tumors.

Conclusions: This study provides a rationale to test AZD3965 in patients with SCLC. Our results suggest that patients with tumors expressing MCT1 and lacking in MCT4 are most likely to respond. Clin Cancer Res; 20(4); 926–37. ©2013 AACR.

Introduction

Small cell lung cancer (SCLC), the most aggressive type of lung cancer, accounts for approximately 15% of lung cancer cases and is responsible for 25% of lung cancer-related deaths (1). Patients frequently present with widespread metastatic disease. Despite initial sensitivity to platinum-etoposide combination therapy, patients with SCLC commonly relapse with progressive chemoresistant disease (2, 3). Despite some progress in characterizing the genetic landscape of SCLC (4–6), this has yet to translate to advances in targeted treatments (7) and there remains pressing need for new approaches to improve outcomes for patients with SCLC.

One promising approach gaining considerable momentum in oncology exploits altered tumor metabolism, now considered a hallmark of cancer (8). SCLC is a prime example of a tumor type likely to be reliant on glycolysis. It has a rapid doubling time (9) indicative of a high rate of cell division, and SCLC tumors often contain regions of hypoxia (10), driving obligate glycolysis (11). SCLC tumors are 2[18F]fluoro-2-deoxy-D-glucose (FDG) avid by positron emission tomography scan (12), consistent with a high uptake of glucose and a glycolytic phenotype. Also, TP53 is frequently mutated and MYC genes are commonly amplified (13). These genes are both associated with a metabolic switch from aerobic respiration to aerobic glycolysis (14, 15).

AZD3965 is an orally bioavailable, monocarboxylate transporter 1 (MCT1)-specific inhibitor, derived from AR-C155858 (16). The MCT proteins, MCT1 and MCT4, are primarily involved in lactate transport (17), and inhibition of MCTs has been proposed to selectively target highly glycolytic cancer cells (18). Previous studies have demonstrated that MCT1 RNA interference (RNAi) causes cell...
Translational Relevance

Small cell lung cancer (SCLC) has dismal prognosis with minimal improvement in treatment for several decades. One attractive strategy is to exploit the altered metabolism of rapidly proliferating and hypoxic tumors by inhibiting lactate transport with monocarboxylate transporter (MCT) inhibitors. The MCT1 inhibitor, AZD3965, is in phase I clinical trial but tests to predict responses are unproven and activity in SCLC is untested. Here, we demonstrate preclinically that hypoxic SCLC cells lacking expression of the alternative lactate transporter, MCT4, are sensitive to AZD3965. In 78 SCLC patients’ tumor biopsies, 21% express MCT1 in hypoxic regions without MCT4, thus predicting response to AZD3965. We also show in these tumors that MCT1 expression correlates with shorter patient survival suggesting that it is a relevant drug target. These data provide rationale for commencing clinical evaluation of AZD3965 in patients with SCLC with assessment of the predictive profile for response.

diluted in water to 1 mg/mL and stored at –20°C. Chloroquine (Sigma) was diluted in water to 50 mmol/L and stored at –20°C.

Concentration response assays

Cells were seeded into 96-well plates, allowed to attach overnight, and where appropriate, transferred to hypoxic conditions for 8 hours before drug treatment for 72 hours. For adherent cells (NCI-H1048 and DMS114), plates were stained with sulforhodamine B (SRB) and processed as previously described (22) to give an indication of cellular biomass. Suspension cells (COR-L103, NCI-H526, NCI-H524, NCI-H146, NCI-H82, DMS79) were subjected to resazurin assay as previously described (23). Fraction unaffected was calculated as the fraction of SRB or resazurin signal at a given AZD3965 concentration compared with untreated cells. A value of 1 represents no effect (i.e., same signal as untreated cells) and 0 total effect (i.e., no cells remaining). To determine log EC50 and minimum fraction unaffected (the fraction unaffected at which increasing concentrations of AZD3965 have no additional affect) log drug concentration was plotted against normalized absorbance/fluorescence and nonlinear curve fit analysis was performed (GraphPad Prism).

Measurements of lactate

A total of 2 × 10^5 cells were resuspended in 50 μL 85% ethanol and incubated on ice for 1 hour, or ground tumor was resuspended in 8 volumes of 85% ethanol and incubated overnight. Extraction was followed by centrifugation for 2 minutes at 13,000 g and supernatant analyzed. Lactate concentration was determined using the L-lactate Assay Kit (Eton Bioscience) according to manufacturer’s instructions.

In vivo efficacy of AZD3965

All experiments were conducted according to Home Office Regulations (United Kingdom) and protocols approved under project license 40-3306. COR-L103 xenografts were grown by subcutaneous injection of 5 × 10^6 cells in 0.2 mL of 1:1 serum-free RPMI:Matrigel (BD Biosciences) into the mid-dorsal flank of 8- to 14-week-old male nonobese diabetic scid-γ mice (Paterson Institute for Cancer Research, Manchester, United Kingdom). Mice were housed in individually vented caging systems in a 12-hour light/12-hour dark environment and maintained at uniform temperature and humidity. Tumor size was measured twice a week using calipers and the volume calculated as tumor length × tumor width^2/2. Thirty days after implantation, mice bearing tumors between 150 and 250 mm^3 were randomized into two groups of six and treated with 100 mg/kg BID AZD3965 in 0.5% hydroxypropyl methyl cellulose, 0.1% tween 80, or vehicle only by oral gavage for 21 days. Measurements were continued three times a week for the duration of drug treatment to assess tumor growth kinetics. At sacrifice tumors were collected to determine intratumor lactate concentration.
Cell-cycle analysis

Pooled detached and adherent cells were fixed with ice-cold 70% ethanol. Fixed cells were incubated with 40 μg/mL propidium iodide and 50 μg/mL RNase A in PBS for 30 minutes at 37°C in the dark. Propidium iodide staining intensity was detected by flow cytometry (BD FACS Calibur), and the percentage of cells in each stage of the cell cycle determined using ModFit LT 3.2 modeling software (Verity Software).

Western blotting

Cell lysis, protein sample preparation, and Western blotting were carried out as previously described (22). Anti-MCT1 and MCT4 antibodies were raised in rabbits inoculated with peptides CPDQKDTEGGPKEEESVP and CEPEKNGEVHITPETS, respectively (supplied by AstraZeneca). Other antibodies used were rabbit anti-cleaved caspase-3 (Cell Signaling Technology), mouse anti-CA IX M75 (a kind gift from Professor Catherine West, Institute of Cancer Sciences, University of Manchester, Manchester, United Kingdom), rabbit anti-LC3 (NB100-2220 Novus Biologicals), and mouse anti-α-tubulin TAT (a kind gift from Professor Keith Gull, Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom).

CK18 ELISA

CK18 is released from dying cells, either as a full-length protein for nonapoptotic forms of cell death or a caspase-cleaved CK18 fragment when cells die by apoptosis. Media from cells were assayed for the presence of total CK18 and caspase-cleaved CK18 using the M65 and M30 Apoptosense ELISAs (Perviva), respectively, as previously described (24).

Generation of an inducible MCT1 and 4 cell line

MCT1 or 4 cDNA was inserted into pENTR3C (Life Technologies) as an EcoRI/BamHI fragment. pENTR3C-MCT1 or pENTR1A-GFP-N2 (Addgene #19364) were recombined with pLenti-CMV-TRE3G-Dest (Addgene #27565; ref. 25) using LR Clonease (Life Technologies) as an EcoRI/BamHI fragment. pENTR3C-MCT4 or pENTR1A-GFP-N2 (Addgene #19364) were recombined with pLenti-CMV-TRE3G-Dest (Addgene #27565; ref. 25) using LR Clonease (Life Technologies) as an EcoRI/BamHI fragment. pENTR3C-MCT1 or 4 cDNA was inserted into pENTR3C (Life Technologies) as an EcoRI/BamHI fragment. pENTR3C-MCT1 or 4 cDNA was inserted into pENTR3C (Life Technologies) as an EcoRI/BamHI fragment. pENTR3C-MCT1 or 4 cDNA was inserted into pENTR3C (Life Technologies) as an EcoRI/BamHI fragment. pENTR3C-MCT1 or 4 cDNA was inserted into pENTR3C (Life Technologies) as an EcoRI/BamHI fragment. pENTR3C-MCT1 or 4 cDNA was inserted into pENTR3C (Life Technologies) as an EcoRI/BamHI fragment. pENTR3C-MCT1 or 4 cDNA was inserted into pENTR3C (Life Technologies) as an EcoRI/BamHI fragment. pENTR3C-MCT1 or 4 cDNA was inserted into pENTR3C (Life Technologies) as an EcoRI/BamHI fragment. pENTR3C-MCT1 or 4 cDNA was inserted into pENTR3C (Life Technologies) as an EcoRI/BamHI fragment. pENTR3C-MCT1 or 4 cDNA was inserted into pENTR3C (Life Technologies) as an EcoRI/BamHI fragment. pENTR3C-MCT1 or 4 cDNA was inserted into pENTR3C (Life Technologies) as an EcoRI/BamHI fragment. pENTR3C-MCT1 or 4 cDNA was inserted into pENTR3C (Life Technologies) as an EcoRI/BamHI fragment. pENTR3C-MCT1 or 4 cDNA was inserted into pENTR3C (Life Technologies) as an EcoRI/BamHI fragment. pENTR3C-MCT1 or 4 cDNA was inserted into pENTR3C (Life Technologies) as an EcoRI/BamHI fragment. pENTR3C-MCT1 or 4 cDNA was inserted into pENTR3C (Life Technologies) as an EcoRI/BamHI fragment. pENTR3C-MCT1 or 4 cDNA was inserted into pENTR3C (Life Technologies) as an EcoRI/BamHI fragment. pENTR3C-MCT1 or 4 cDNA was inserted into pENTR3C (Life Technologies) as an EcoRI/BamHI fragment. pENTR3C-MCT1 or 4 cDNA was inserted into pENTR3C (Life Technologies) as an EcoRI/BamHI fragment. pENTR3C-MCT1 or 4 cDNA was inserted into pENTR3C (Life Technologies) as an EcoRI/BamHI fragment. pENTR3C-MCT1 or 4 cDNA was inserted into pENTR3C (Life Technologies) as an EcoRI/BamHI fragment. pENTR3C-MCT1 or 4 cDNA was inserted into pENTR3C (Life Technologies) as an EcoRI/BamHI fragment. pENTR3C-MCT1 or 4 cDNA was inserted into pENTR3C (Life Technologies) as an EcoRI/BamHI fragment. pENTR3C-MCT1 or 4 cDNA was inserted into pENTR3C (Life Technologies) as an EcoRI/BamHI fragment. pENTR3C-MCT1 or 4 cDNA was inserted into pENTR3C (Life Technologies) as an EcoRI/BamHI fragment. pENTR3C-MCT1 or 4 cDNA was inserted into pENTR3C (Life Technologies) as an EcoRI/BamHI fragment. pENTR3C-MCT1 or 4 cDNA was inserted into pENTR3C (Life Technologies) as an EcoRI/BamHI fragment. pENTR3C-MCT1 or 4 cDNA was inserted into pENTR3C (Life Technologies) as an EcoRI/BamHI fragment. pENTR3C-MCT1 or 4 cDNA was inserted into pENTR3C (Life Technologies) as an EcoRI/BamHI fragment. pENTR3C-MCT1 or 4 cDNA was inserted into pENTR3C (Life Technologies) as an EcoRI/BamHI fragment. pENTR3C-MCT1 or 4 cDNA was inserted into pENTR3C (Life Technologies) as an EcoRI/BamHI fragment. pENTR3C-MCT1 or 4 cDNA was inserted into pENTR3C (Life Technologies) as an EcoRI/BamHI fragment. pENTR3C-MCT1 or 4 cDNA was inserted into pENTR3C (Life Technologies) as an EcoRI/BamHI fragment. pENTR3C-MCT1 or 4 cDNA was inserted into pENTR3C (Life Technologies) as an EcoRI/BamHI fragment.

siRNA transfection

Cells were transfected with siRNAs targeted to MCT4 and nontargeting control siRNA (Thermo Scientific) using Lipofectamine RNAiMAX (Life Technologies) according to the manufacturer’s instructions. After 24 hours siRNA-treated cells were replated for further experiments.

Tissue microarray construction

Archival SCLC biopsy specimens and clinical data from 78 patients presenting to the University Hospital of South Manchester and the Christie Hospital (Manchester, United Kingdom) between 1994 and 2005 were retrieved, processed, and analyzed according to local ethical approvals. Hematoxylin and eosin-stained sections for each tumor were examined by a clinically accredited pathologist, with specialization in lung cancer (D. Nonaka). Nine 1 mm diameter representative cores from the tumor specimens were cut and placed randomly in tissue microarrays (TMA) recipient blocks to generate three TMA. In addition to examining morphology, SCLC histology was confirmed by immunohistochemical (IHC) analysis for cytokeratin, CD56, and synaptophysin.

Immunohistochemistry

Formalin-fixed paraffin-embedded 4 μm sections were prepared from the TMA or cell line pellets. For MCT1 and MCT4 staining, sections were dewaxed, rehydrated, antigen retrieval carried out by incubating in 10 mmol/L Citric Acid:NaOH (pH 6.0) for 15 minutes at 98°C, and endogenous peroxidase blocked with 3% H2O2 for 15 minutes. Slides were blocked with serum-blocking solution (Dako) for 30 minutes and incubated with 1:500 rabbit anti-MCT1, 1:250 rabbit anti-MCT4 in PBST for 1 hour. Secondary antibody from the Envision Kit (Dako) was applied for 30 minutes and staining was visualized by incubation in DAB solution (Dako) for 3 minutes. Slides were counterstained with hematoxylin, dehydrated, and mounted. Additional immunohistochemistry was carried out for Carbonic Anhydrase IX (rabbit polyclonal, NB100-417, 1:2000; Novus Biologicals), cytokeratins (mouse AE1/AE3, M3515, 1:60, Dako), CD56 (mouse 1B6, NCL-CD56-1B6, 1:100; Novoceastra), and synaptophysin (mouse 27G12, NCL-L-SYNAP-299, 1:200; Novoceastra). Antibody incubations and detection were carried out at room temperature on a Menarini IntelliPATH FLX (A. Menarini Diagnostics) using Menarini’s reagent buffer and detection kits unless otherwise noted. Antigen retrieval was performed in a pressure cooker using access super retrieval fluid (MP-606-PG1) for all antisera except AE1/AE3, which was 10-minute incubation with protease (MP-960-K15) on IntelliPATH.

Analysis of IHC staining

Staining was evaluated by two independent scorers (one of which was a clinical pathologist, D. Nonaka) without knowledge of demographic or outcome data. Extent of IHC staining was categorized as 0% (0), 1% to 25% (1), 26% to 50% (2), 51% to 75% (3), or 76% to 100% (4), and intensity of IHC staining as absent (0), weak (1), moderate (2), or strong (3). Completely crushed and necrotic cores and cores where one or more scorer failed to score were removed. A combined score for each case was calculated as the mean product of extent and intensity for all the cores in a case.
Sensitivity of SCLC cell lines to AZD3965

A panel of seven SCLC cell lines was constructed to reflect the mutations in TP53, RB1, and MYC family genes that are common in SCLC (Supplementary Table S1). To assess the efficacy of AZD3965 (Supplementary Fig. 1), these cell lines were cultured under normoxic or hypoxic (1% O2) conditions and exposed for 72 hours to 8 nmol/L AZD3965, a concentration of AZD3965 that inhibited MCT1 activity (data not shown). Generally, cells cultured under hypoxic conditions were more sensitive to AZD3965 than their normoxic counterparts (Fig. 1A). There was a wide range of responses of hypoxic cells to AZD3965, with COR-L103, NCI-H526, and NCI-H1048 being relatively sensitive and DMS114, DMS79, and NCI-H146 relatively resistant. NCI-H526, NCI-H1048, NCI-H524, and NCI-H146 cells also demonstrated a reproducible response to AZD3965 under hypoxic conditions.

On the basis of the cell panel data, four cell lines were chosen for further analysis, two which were sensitive to AZD3965 under hypoxia (COR-L103 and NCI-H1048) and two which were relatively AZD3965 resistant (DMS79 and DMS114). Concentration response experiments (Fig. 1B) demonstrated that COR-L103 were exquisitely sensitive to AZD3965 but only under hypoxic conditions. NCI-H1048 cells were more sensitive to AZD3965 under hypoxic conditions. NCI-H1048 cells were more sensitive to AZD3965 under hypoxic conditions although the minimum

Statistical analysis

Statistical analysis of preclinical studies was carried out with unpaired two-tailed t tests unless otherwise specified using GraphPad Prism software and a P < 0.05 was considered statistically significant. The association between MCT1, MCT4, or CA IX and known prognostic factors [stage, Hb < 9 g/L, WBC > 10 x 10^9/L, platelets < 150 x 10^9/L, Na < 135 mmol/L; lactate dehydrogenase (LDH) > 550 IU/L] was evaluated by Fisher exact test. Kaplan–Meier analysis was used to assess overall survival (OS) rates, and log-rank test was used for the comparison of the survival distributions. Multivariate analysis was performed using the Cox regression model. Death was defined as the time from biopsy to the time of death. Death due to other causes than SCLC was censored. A P ≤ 0.05 was considered statistically significant. The statistical analysis was performed by SPSS version 20 (SPSS Inc.)

Results

Sensitivity of SCLC cell lines to AZD3965

A panel of seven SCLC cell lines was constructed to reflect the mutations in TP53, RB1, and MYC family genes that are common in SCLC (Supplementary Table S1). To assess the efficacy of AZD3965 (Supplementary Fig. 1), these cell lines were cultured under normoxic or hypoxic (1% O2) conditions and exposed for 72 hours to 8 nmol/L AZD3965, a concentration of AZD3965 that inhibited MCT1 activity (data not shown). Generally, cells cultured under hypoxic conditions were more sensitive to AZD3965 than their normoxic counterparts (Fig. 1A). There was a wide range of responses of hypoxic cells to AZD3965, with COR-L103, NCI-H526, and NCI-H1048 being relatively sensitive and DMS114, DMS79, and NCI-H146 relatively resistant. NCI-H526, NCI-H1048, NCI-H524, and NCI-H146 cells also demonstrated a reproducible response to AZD3965 under hypoxic conditions.

On the basis of the cell panel data, four cell lines were chosen for further analysis, two which were sensitive to AZD3965 under hypoxia (COR-L103 and NCI-H1048) and two which were relatively AZD3965 resistant (DMS79 and DMS114). Concentration response experiments (Fig. 1B) demonstrated that COR-L103 were exquisitely sensitive to AZD3965 but only under hypoxic conditions. NCI-H1048 cells were more sensitive to AZD3965 under hypoxic conditions although the minimum

Figure 1. Response to AZD3965 correlated with increased intracellular lactate. A, normoxic (white) or hypoxic (1% O2, black) SCLC cell lines were treated with 8 nmol/L AZD3965 for 72 hours and the effect of drug relative to vehicle-treated cells determined by SRB assay (NCI-H1048 and DMS114 – adherent cells) or resazurin assay (other cell lines – suspension cells). Data are presented as one fraction of cells unaffected by AZD3965 relative to untreated control. B–D, normoxic or hypoxic

COR-L103, NCI-H1048, DMS79, or DMS114 were treated for 72 hours

www.aacrjournals.org

Clin Cancer Res; 20(4) February 15, 2014 929

Downloaded from clincancerres.aacrjournals.org on October 2, 2017. © 2014 American Association for Cancer Research.
fraction unaffected was the same in both environments and higher than COR-L103 cells in hypoxia. Of the two resistant cell lines, DMS114 exhibited a modest response to AZD3965 under hypoxic conditions, whereas DMS79 showed no response until >100 nmol/L AZD3965. Because of the fact that COR-L103 and DMS79 grow in suspension, it was necessary to utilize the resazurin assay to determine the effect of AZD3965. However, resazurin reduction can be influenced by the metabolic activity of cells and is therefore not necessarily a robust readout of cell number. Therefore, to determine whether the effect of AZD3965 was due to reduced cell number, the effect of 8 nmol/L AZD3965 on cell number was determined in the four cell lines cultured under normoxic or hypoxic conditions (Fig. 1C). Consistent with the concentration response data, AZD3965 treatment caused a statistically significant reduction in hypoxic COR-L103 ($P$ = 0.002), normoxic ($P$ = 0.011), hypoxic ($P$ = 0.0023) NCI-H1048, and hypoxic DMS114 cells ($P$ = 0.038).

As the primary substrate for MCT1-mediated transport is lactate, the effect of AZD3965 treatment on intracellular lactate was determined (Fig. 1D). AZD3965 treatment caused a 3.7-fold increase in intracellular lactate in hypoxic COR-L103 and 3.7-fold and 3.9-fold increases in normoxic and hypoxic NCI-H1048 cells, respectively. In all other cases, a <1.9-fold increase was observed. These data are consistent with AZD3965-blocking lactate transport in cells where AZD3965 also reduces cell number and is consistent with AZD3965 acting via inhibition of MCT1.

To further confirm that AZD3965 targeted MCT1, NCI-H1048 cells were engineered to inducibly overexpress MCT1. If AZD3965 targeted MCT1, we predicted that overexpressing MCT1 would lead to AZD3965 resistance, as more AZD3965 would be required to effectively inhibit all MCT1. Indeed, when MCT1 was overexpressed (Supplementary Fig. S2A), the EC$_{50}$ of NCI-H1048 was increased from 0.14 to 10.5 nmol/L (Supplementary Fig. S2B). This is consistent with AZD3965 acting via MCT1 inhibition.

**In vivo efficacy of AZD3965**

COR-L103 xenograft studies were carried out to determine whether the *in vitro* effect of AZD3965 was recapitulated *in vivo*. COR-L103 tumor-bearing mice were treated with 100 mg/kg AZD3965 or vehicle *BID* for 21 days and the tumor volume monitored. Pharmacokinetic analysis demonstrated that 100 mg/kg AZD3965 *BID* resulted in concentrations of free AZD3965 predicted to inhibit lactate transport (data not shown). AZD3965 treatment significantly reduced the growth of COR-L103 tumors (Fig. 2A; $P < 0.0001$; two-way ANOVA), although tumor regression was not seen, consistent with AZD3965 only targeting the hypoxic fraction of the tumor. Analysis of lactate concentration at sacrifice confirmed that the reduced tumor growth rate was accompanied by a significant increase in intratumor lactate (Fig. 2B; $P = 0.0038$) consistent with the *in vitro* observation that AZD3965 affected hypoxic COR-L103 cell proliferation/survival and increased intracellular lactate.

**Cell fate of AZD3965-treated SCLC cells**

To define the nature of the response to MCT1 inhibition, the cell-cycle profile of cells cultured in normoxia or hypoxia and treated with AZD3965 were determined by flow cytometry (Fig. 3A and Supplementary Fig. S3). AZD3965 had no effect on the cell-cycle phase distribution of DMS114 or DMS79 cells cultured in normoxic or hypoxic conditions or on COR-L103 cells cultured in normoxic conditions. However, significant increase in the proportion of cells with sub-$G_1$ DNA content was detected after AZD3965 treatment in both COR-L103 and NCI-H1048 cells cultured in hypoxia and NCI-H1048 cells under normoxia. Increased sub-$G_1$ was most pronounced in COR-L103, which correlated with the effect of AZD3965 reported in Fig. 1. To investigate whether the sub-$G_1$ population of cells was caused by AZD3965-induced apoptosis, the four cell lines cultured in normoxia and hypoxia and treated with AZD3965 were assayed for the presence of cleaved caspase-3 by Western blotting (Fig. 3B). Untreated hypoxic NCI-H1048 and normoxic DMS114 showed evidence of cleaved caspase-3.

![Figure 2](clincancerres.aacrjournals.org) AZD3965 inhibited COR-L103 xenograft growth and increased intratumor lactate concentration. COR-L103 xenograft-bearing mice were treated with 100 mg/kg *BID* AZD3965 or vehicle and the effect on (A) tumor volume or (B) intratumor lactate after 21 days of treatment was determined. $N$ = 6 for vehicle and $N$ = 7 for AZD3965-treated groups (two vehicle-treated animals were sacrificed early so are excluded from lactate concentration analysis). A, **; $P = 0.001$ according to two-way ANOVA. B, ***; $P < 0.001$ according to a two-tailed t test.
caspase-3, suggesting a degree of spontaneous apoptosis in hypoxic NCI-H1048 and normoxic DMS114. However, AZD3965 did not affect the level of cleaved caspase-3 in any cell line under normoxic or hypoxic conditions. Treatment of COR-L103 cells with the broad spectrum caspase inhibitor Q-VD-OPh did not affect the concentration response under normoxia or hypoxia (Fig. 3C). Furthermore, although AZD3965 treatment of hypoxic COR-L103 cells led to accumulation of CK18 in the media, a general marker of cell death (26), it was not the caspase cleaved form of CK18 (Fig. 3D) consistent with the observed cell death being nonapoptotic.

If AZD3965 did not cause cell death via apoptosis, we reasoned that it may cause autophagy, eventually leading to cell death. To test this hypothesis, normoxic and hypoxic COR-L103, NCI-H1048, DMS114, and DMS79 cells were treated with AZD3965 or vehicle control, with and without chloroquine. Chloroquine raises the lysosomal pH, preventing completion of autophagy and therefore making any changes to the rate of autophagy easier to detect. The effect of AZD3965 and/or chloroquine on the level of the autophagic marker LC3-II was assessed by Western blotting (Supplementary Fig. S4). In all cases, chloroquine increased the level of LC3-II, consistent with a degree of background autophagy occurring in all cell lines in both normoxia and hypoxia. However, there was no evidence of AZD3965 affecting the level of LC3-II, regardless of chloroquine treatment. This suggests that AZD3965 does not cause autophagy. Taken together, these data suggest that AZD3965 treatment induced a nonapoptotic, non-autophagic form of cell death, most likely necrotic cell death, in hypoxic COR-L103 and NCI-H1048, which may

Figure 3. AZD3965 induced nonapoptotic cell death in hypoxic COR-L103. A, normoxic or hypoxic COR-L103, NCI-H1048, DMS79, or DMS114 cells were treated with 8 nmol/L AZD3965 for 72 hours. Ethanol fixed cells were stained with propidium iodide and the cell-cycle profile determined by flow cytometry. B, normoxic or hypoxic COR-L103, NCI-H1048, DMS79, and DMS114 cells were treated with 8 nmol/L AZD3965 for 72 hours and the level of cleaved caspase-3 assayed by Western blot analysis. Tubulin is used as a loading control. C, normoxic or hypoxic COR-L103 cells were treated with the indicated concentration of AZD3965 as in Fig. 1B plus 10 μmol/L Q-VD-OPh or DMSO equivalent. D, normoxic and hypoxic COR-L103 were treated with 8 nmol/L AZD3965 for 72 hours and the media assayed for the presence of total or caspase-cleaved CK18. Blots are representative of three independent experiments. All graphs represent mean of three independent experiments ± SEM. *, P < 0.05; **, P < 0.01 according to a paired two-tailed t test.
account for the efficacy of AZD3965 reported in Figs. 1 and 2.

**Role of MCT4 in SCLC resistance to AZD3965**

Previous reports in other cancer types have implicated MCT4 expression as a resistance factor for MCT1 inhibition (21), and MCT4 expression is upregulated by hypoxia-inducible factor-1α (HIF-1α) in hypoxia (27). To determine whether there is a correlation between MCT1 and MCT4 expression and response to AZD3965 in SCLC, MCT1 and MCT4 expression levels under normoxic and hypoxic conditions in the presence and absence of AZD3965 were assessed by Western blot analysis (Fig. 4A). Although MCT4 expression was undetectable in COR-L103 and NCI-H1048 cells, regardless of oxygen concentration or AZD3965 treatment, MCT4 expression was detectable in normoxic DMS79 cells and hypoxia increased MCT4 expression in both DMS114 and DMS79 cells. Furthermore, hypoxic MCT4 expression correlated with fraction unaffected by 8 nmol/L AZD3965 across the full panel of cell lines (Supplementary Fig. S5; \(P = 0.003\)). IHC staining of COR-L103 xenografts demonstrated that the tumor also expressed high levels of MCT1 but not MCT4 (Supplementary Fig. S6). It is interesting to note that the level of MCT1 increased in hypoxic DMS114 cells, although the reason for this is unclear.

Two approaches were taken to test whether MCT4 caused AZD3965 resistance in SCLC cells. First, the effect of MCT4 overexpression in the AZD3965-sensitive cell line NCI-H1048 was determined. NCI-H1048 cells were engineered to inducibly overexpress GFP or MCT4 in response to doxycycline treatment (Fig. 4B). The effect of GFP or MCT4 overexpression on AZD3965 efficacy was determined (Fig. 4C). Under hypoxic conditions, GFP expression did not affect the minimum fraction unaffected (0.443 GFP No doxycycline vs. 0.405 GFP doxycycline; \(P = 0.522\)), whereas MCT4 overexpression significantly increased the minimum fraction unaffected by 8 nmol/L AZD3965 across the full panel of cell lines (Supplementary Fig. S5; \(P = 0.003\)).

The results presented here suggest that MCT4 plays a role in SCLC resistance to AZD3965. Further studies are needed to elucidate the mechanism by which MCT4 contributes to resistance and to explore potential therapeutic strategies targeting MCT4.

**Figure 4.** Hypoxia-induced MCT4 expression correlated with resistance to AZD3965 and MCT4 overexpression caused AZD3965 resistance. A, normoxic or hypoxic COR-L103, NCI-H1048, DMS79, or DMS114 cells were treated with 8 nmol/L AZD3965 for 72 hours. Expression of MCT1 and MCT4 protein was assayed by Western blotting. Tubulin was used as a loading control. B–D, NCI-H1048 cells engineered to overexpress GFP or MCT4 upon the addition of doxycycline (Dox) were cultured under normoxia or hypoxia and treated with 1 μg/mL doxycycline alone (B) or with the indicated concentration of AZD3965 (C) or 8 nmol/L AZD3965 (D). MCT4 and CA IX expression was assayed by Western blotting with tubulin used as a loading control (B). Cellular biomass was determined as in Fig. 1B (C). Intracellular lactate was measured as in Fig. 1D and expressed relative to untreated normoxic or hypoxic cells (D). Blots are representative of three independent experiments. All graphs represent mean of at least three independent experiments ± SEM. *, \(P < 0.05\) according to a paired two-tailed t test.
fraction unaffected (0.572 MCT4 No doxycycline vs. 0.761 MCT4 doxycycline; \( P = 0.035 \)). Furthermore, the level of intracellular lactate in hypoxic cells following AZD3965 treatment (Fig. 4D) was not affected by GFP expression (2.7-fold GFP No doxycycline vs. 2.7-fold GFP doxycycline; \( P = 0.91 \)) but was significantly decreased in MCT4 overexpressing cells (3.9-fold MCT4 No doxycycline vs. 2.5-fold MCT4 doxycycline; \( P = 0.01 \)). Together these data suggest that MCT4 overexpression can induce AZD3965 resistance in hypoxic NCI-H1048 SCLC cells.

The effect of MCT4 RNAi on AZD3965 sensitivity was assessed to determine whether MCT4 expression was the cause of AZD3965 resistance in DMS79 and DMS114 cells. MCT4 RNAi depleted MCT4 in both DMS114 and DMS79 cells under normoxic and hypoxic conditions (Fig. 5A). In both cases, MCT4 knockdown increased the sensitivity to AZD3965 (Fig. 5B), with the minimum fraction unaffected decreasing in DMS114 from 0.73 in hypoxic control cells to 0.464 in hypoxic MCT4 RNAi cells (\( P = 0.01 \)) and in DMS79 from 0.94 in hypoxic control cells to 0.75 in MCT4 RNAi hypoxic cells (\( P = 0.0002 \)). Increased AZD3965 sensitivity was associated with a significant increase in intracellular lactate in hypoxic cells treated with AZD3965 (Fig. 5C). Specifically, in hypoxic DMS114 cells, AZD3965 caused a 1.8-fold lactate increase in control cells and a 2.8-fold lactate increase in MCT4 RNAi cells (\( P = 0.002 \)). In both cell lines, MCT4 knockdown alone did not cause a significant increase in intracellular lactate levels, suggesting that MCT1 and MCT4 are both able to transport lactate in these cells. Taken together, the analysis of endogenous MCT4 expression, MCT4 overexpression, and MCT4 RNAi data strongly suggest that MCT4 expression in hypoxic SCLC cells caused resistance to MCT1 inhibition by AZD3965.

Evaluation of hypoxia, MCT1, and MCT4 in SCLC patient biopsies

The preclinical data suggest that SCLC tumors that express MCT1 but not MCT4 in hypoxic regions may be most sensitive to growth inhibition by AZD3965. To determine whether this is a phenotype observed in patients with SCLC, a TMA, generated from tumor cores from 78 patients with SCLC, was stained by immunohistochemistry for expression of MCT1, MCT4, and for the hypoxia marker CA IX (28). Specificity of MCT1 and MCT4 staining was first demonstrated in cell lines with known MCT1 and MCT4 expression levels (Supplementary Fig. S7). MCT1, MCT4, and CA IX staining of the TMA revealed the expected plasma membrane staining for all three markers (Supplementary Fig. S8A). The TMA was assessed by two independent scorers using predetermined scoring criteria (see Materials and Methods and Supplementary Fig. S8B). Correlation between scorers was evaluated by the Pearson test and in all cases has highly significant (Supplementary Fig. S9A).
The results demonstrated heterogeneous expression levels for MCT1, MCT4, and CA IX. The proportion of tumors with any expression of MCT1, MCT4, or CA IX was 99%, 99%, and 90%, respectively. The level of MCT1, MCT4, or CA IX expression was quantified by multiplying the extent and intensity scores for a core and calculating the mean value for all cores from a patient. Higher levels of expression were observed for MCT1 (median = 8.17) compared with MCT4 (median = 2.21; paired t test \( P < 0.0001 \); Supplementary Fig. S9B). A positive correlation was observed for CA IX expression and MCT4 expression (Pearson \( R^2 = 0.146, P = 0.0005 \); Fig. 6A, top; and Supplementary Fig. S10); consistent with our previous observation in vitro that hypoxia can increase MCT4 levels in SCLC. However, tumors with CA IX expression, high MCT1 expression (>median), and low MCT4 expression (<median) were present, representing 21% of the cases in this cohort. This defined a putative subpopulation of SCLC with higher chance of response to MCT1 inhibition by AZD3965, according to our preclinical findings (Fig. 6A, bottom; Fig. 6B).

Clinical significance of MCT1, MCT4, and CA IX expression in SCLC

To explore the association of MCT1, MCT4, or CA IX expression with clinical demographics, clinical prognostic factors, and OS, data were available for 47 of the 78 patients scored for MCT expression (Supplementary Table S2). Patients were stratified into MCT1 high/low, MCT4 high/low, or CA IX high/low based on the median score from the complete TMA dataset. No significant correlation was observed for MCT1, MCT4, or CA IX with known clinical prognostic factors (stage, Hb <9 g/L, WBC >10 \( \times \) 10\(^9\)/L, platelets <150 \( \times \) 10\(^9\)/L, Na <135 mmol/L; LDH >550 IU/L; data not shown). However, MCT1 expression score was associated with worse survival with a median survival of 9 months for MCT1 expression >median compared with 15 months for MCT1 expression <median; (log-rank \( P = 0.014 \); Fig. 6C). Neither MCT4 nor CA IX expression was prognostic (Fig. 6D and Supplementary Fig. S11A). Of the known prognostic factors assessed, extensive stage was associated with shorter OS (Supplementary Fig. S11B; median survival 2 months vs. 14 months; \( P < 0.0001 \)), whereas a trend toward poorer prognosis was observed for patients with LDH >550 IU/L (Supplementary Fig. S11C). Multivariate analysis was performed on 29 patients. Stage, MCT1 expression, and LDH level were included as they were significant or showed a trend toward significance in the univariate analysis. None of the variables remained significant in the multivariate analysis [stage HR = 3.62; confidence interval (CI), 0.995–13.18 \( P = 0.051 \), MCT1 HR = 0.646 (CI 0.27–1.57) \( P = 0.333 \), LDH HR = 0.599 (CI 0.266–1.35) \( P = 0.216 \)].

Discussion

Aberrations in cellular metabolism have been acknowledged recently as a hallmark of cancer (8), which is highlighted by the number of novel therapies targeting cancer metabolism currently in development (18). One such approach pertinent to SCLC is perturbation of...
glycolytic tumor metabolism. Cancer cells frequently rely on glycolysis, rather than oxidative phosphorylation, for ATP generation, a phenomenon termed the Warburg effect (29), to shunt carbon into biosynthetic pathways essential for rapid cell growth and division (30). Dependency on glycolysis is further enhanced by obligate glycolysis in hypoxic cells, a common occurrence in tumors with compromised vascular architecture (31). One consequence of increased glycolysis/reduced oxidative phosphorylation is increased lactate production. Lactate must be transported from the cell to prevent intracellular acidification or inhibition of metabolic pathways due to negative regulation caused by high lactate levels (18). MCT1 plays an important role in metabolism by facilitating diffusion of monocarboxylates, such as lactate, across the plasma membrane, and MCT1 expression is prevalent in tumors compared with normal tissues (32). Previous work suggested that MCT1 may be an effective target for therapeutic intervention of glycolytic tumor cells (19, 20). In the present study, we tested the small-molecule MCT1 inhibitor AZD3965 in a panel of SCLC cell lines in anticipation that these cells, derived from highly aggressive, rapidly proliferating and often hypoxic tumors, will be reliant on glycolysis and thus vulnerable to inhibition of MCT1.

Our data demonstrate that some, but not all, SCLC cell lines respond to MCT1 inhibition and are particularly sensitive when hypoxic and therefore obligate glycolytic. We confirmed that the sensitivity of the COR-L103 cells to AZD3965 in vitro translated to an in vivo model, where increased intratumor lactate provided proof of mechanism. Furthermore, high expression of the HIF1-α-inducible member of the MCT family, MCT4, is associated with resistance to AZD3965 in SCLC. Importantly, MCT4 overexpression led to AZD3965 resistance and MCT4 knockdown caused AZD3965 sensitization, confirming that MCT4 is a bona fide AZD3965 resistance factor. These findings are in line with previously published data obtained in other cell types and consistent with functional redundancy between MCT1 and MCT4 (21). These data raised the question of whether, in hypoxic clinical samples, MCT1 expression can occur in the absence of MCT4, thus predicting an AZD3965-sensitive population. We observed a correlation between MCT4 and CA IX expression, reinforcing the relationship between hypoxia and MCT4 expression in the clinical setting. However, we also demonstrated that 21% of SCLC tumors with hypoxic regions exhibit a MCT1-high, MCT4-low phenotype.

The expression and clinical significance of MCT1 and MCT4 has not previously been reported for SCLC. Our data suggest that MCT1 expression is associated with worse survival reinforcing that MCT1 is a relevant drug target for this disease, although it was not possible to assess whether MCT1 was an independent poor prognostic factor due to the small sample of patients included in the multivariate analysis. Other studies have previously demonstrated that MCT1 and MCT4 expression changes with cancer progression, although whether levels increase or decrease relative to normal tissue depends on cancer type (32). Two studies have correlated MCT1 expression with known prognostic markers in basal-like breast carcinoma (33) and prostate cancer (34). However, to our knowledge, this is the first description of an association between MCT1 and worse OS in any type of cancer.

Taken together, our preclinical and clinical data provide a rationale to test AZD3965 in patients with SCLC. It also identifies a profile of high MCT1 in hypoxic regions in the absence/low expression of MCT4 in tumors as a potential predictive biomarker profile for patient selection to test clinically. The ability to identify molecularly defined subpopulations for targeted drug development has accelerated development of novel therapies for other cancers, for example in non–small cell lung cancer (NSCLC) with the clinical development of crizotinib for NSCLC bearing ALK gene fusion (35). Furthermore, the evaluation of targeted therapies in unselected SCLC patient cohorts has likely contributed to the universally negative trial results to date (36). Our results provide rational to select patients for clinical trials based on MCT1, MCT4, and CA IX tumor expression.

We also confirmed that SCLC cells and tumor xenograft accumulate high levels of intracellular lactate in response to AZD3965 in vitro and in vivo, respectively. This implies that monitoring intratumor lactate concentration will serve as a pharmacodynamic biomarker using noninvasive nuclear magnetic resonance spectroscopy-based techniques to measure metabolite levels in patients’ tumors (37).

Serum levels of LDH, the enzyme responsible for converting pyruvate into lactate, is a known independent prognostic factor in SCLC (38). Although serum LDH most likely reflects tumor burden, it may be further affected by a highly hypoxic and/or glycolytic tumor (39). Indeed, FDG avidity, a marker of glycolysis, is also associated with worse prognosis in patients with SCLC (40). Of further interest are the findings that high levels of tumor lactate are associated with increased metastatic rate and worse survival in patients with cervical and head and neck cancer (41, 42). These data suggest that patients with highly glycolytic tumors have a poorer outcome, supporting the notion of targeting glycolytic tumor cells in SCLC. Our results provide a rational for clinical evaluation of AZD3965 in patients with SCLC, incorporating measurement of MCT1 and MCT4 expression, intratumor lactate, serum LDH, and FDG avidity as putative predictive and pharmacodynamic biomarkers.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: R. Polański, S.E. Critchlow, P.D. Smith, F. Blackhall, C. Dive, C.J. Morrow
Development of methodology: R. Polański, D. Nonaka, F. Blackhall
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): R. Polański, C.L. Hodgkinson, D. Nonaka, L. Priest, P. Kelly, P.W. Bishop, A. White, F. Blackhall
Analysis and interpretation of data (e.g., statistical analysis, bio-statistics, computational analysis): R. Polański, C.L. Hodgkinson, A. Fusi, D. Nonaka, F. Trapani, F. Blackhall, C. Dive, C.J. Morrow

www.aacrjournals.org
Clin Cancer Res; 20(4) February 15, 2014
935

Published OnlineFirst November 25, 2013; DOI: 10.1158/1078-0432.CCR-13-2270
Downloaded from clincancerres.aacrjournals.org on October 2, 2017. © 2014 American Association for Cancer Research.
Writing, review, and/or revision of the manuscript: R. Polanski, A. Fusi, D. Nonaka, P.D. Smith, F. Blackhall, C. Dive, C.J. Morrow
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): C.L. Hodgkinson, A. Fusi, D. Nonaka
Study supervision: D. Nonaka, F. Blackhall, C. Dive, C.J. Morrow

Acknowledgments
The authors thank Bedzy Bola, Amy Chadwick, and Ian Stratford for helpful discussion of the data.

References

Grant Support
This work was supported by CR-UK core funding to the Paterson Institute for Cancer Research (C147/A12328) to C. Dive.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received August 16, 2013; revised November 6, 2013; accepted November 7, 2013; published OnlineFirst November 25, 2013.


Activity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer

Radoslaw Polanski, Cassandra L. Hodgkinson, Alberto Fusi, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-13-2270

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2013/11/25/1078-0432.CCR-13-2270.DC1

Cited articles
This article cites 41 articles, 14 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/20/4/926.full#ref-list-1

Citing articles
This article has been cited by 9 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/20/4/926.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.